DOCSLIB.ORG

19 CSR 30-1.042 Inventory Requirements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Rules of Department of Health and Senior Services Division 30—Division of Regulation and Licensure Chapter 1—Controlled Substances Title Page 19 CSR 30-1.002 Schedules of Controlled Substances .........................................................3 19 CSR 30-1.004 List of Excepted Substances.................................................................13 19 CSR 30-1.006 List of Exempt Anabolic Steroid Products................................................13 19 CSR 30-1.008 List of Excluded Veterinary Anabolic Steroid Implant Products......................14 19 CSR 30-1.010 Schedules of Controlled Substances (Rescinded November 30, 2000)...............14 19 CSR 30-1.011 Definitions......................................................................................15 19 CSR 30-1.013 Miscellaneous Fees ...........................................................................16 19 CSR 30-1.015 Registrations and Fees........................................................................16 19 CSR 30-1.017 Registration Process ..........................................................................16 19 CSR 30-1.019 Registration Location.........................................................................19 19 CSR 30-1.020 List of Excepted Substances (Rescinded November 30, 2000)........................19 19 CSR 30-1.023 Registration Changes .........................................................................19 19 CSR 30-1.025 List of Exempt Anabolic Steroid Products (Rescinded November 30, 2000).......20 19 CSR 30-1.026 Separate Registrations ........................................................................20 19 CSR 30-1.027 Investigative and Administrative Procedures .............................................21 19 CSR 30-1.030 Requirements for Controlled Substances Registration (Rescinded November 30, 2000) ..........................................................21 19 CSR 30-1.031 Physical Security Requirements.............................................................21 19 CSR 30-1.032 Security for Nonpractitioners ...............................................................21 19 CSR 30-1.033 Hearing Procedures on Controlled Substances Registration (Rescinded November 30, 2000) ..........................................................22 JOHN R. ASHCROFT (5/31/21) CODE OF STATE REGULATIONS 1 Secretary of State 19 CSR 30-1.034 Security for Practitioners ....................................................................22 19 CSR 30-1.035 Requirements for Prescribing, Dispensing and Administering Controlled Substances (Rescinded November 30, 2000) ...............................23 19 CSR 30-1.036 Disposing of Unwanted Controlled Substances (Rescinded November 30, 2000) ..........................................................23 19 CSR 30-1.040 Dispensing and Distribution of Controlled Substances in Certain Situations (Rescinded July 30, 2003) ..................................................................23 19 CSR 30-1.041 Records Requirements........................................................................23 19 CSR 30-1.042 Inventory Requirements ......................................................................23 19 CSR 30-1.044 Continuing Records General Requirements...............................................25 19 CSR 30-1.046 Records for Manufacturers, Distributors, Importers and Exporters ..................25 19 CSR 30-1.048 Records for Practitioners and Researchers................................................26 19 CSR 30-1.050 Records for Chemical Analysts .............................................................27 19 CSR 30-1.052 Records for Long-Term Care Facilities (LTCF)..........................................27 19 CSR 30-1.060 Determining Lawful Prescribing, Dispensing and Administering of Controlled Substances....................................................................28 19 CSR 30-1.062 Transmission of Prescriptions...............................................................28 19 CSR 30-1.064 Partial Filling of Controlled Substance Prescriptions ...................................28 19 CSR 30-1.066 Dispensing by Individual Practitioners ....................................................29 19 CSR 30-1.068 Administering In Emergency Rooms.......................................................29 19 CSR 30-1.070 Emergency Dispensing of Schedule II Substances.......................................29 19 CSR 30-1.072 Dispensing of Schedule V Substances .....................................................30 19 CSR 30-1.074 Dispensing Without a Prescription .........................................................30 19 CSR 30-1.076 Emergency Distribution by a Pharmacy ...................................................32 19 CSR 30-1.078 Disposing of Unwanted Controlled Substances ..........................................32 19 CSR 30-1.080 Electronic Prescribing Waiver ..............................................................33 2 CODE OF STATE REGULATIONS (5/31/21) JOHN R. ASHCROFT Secretary of State Chapter 1—Controlled Substances 19 CSR 30-1 Title 19—DEPARTMENT OF K. Alpha-methylthiofentanyl PP. 3-Methylfentanyl (N-(3- HEALTH AND SENIOR SERVICES (N-(1-methyl-2-(2-thienyl) methyl-1-(2-phenylethyl)- Division 30—Division of ethyl-4-piperidinyl)-N- 4-piperidyl)-N- Regulation and Licensure phenylpropanamide) 9832 phenylproanamide), its Chapter 1—Controlled Substances L. Benzethidine 9606 optical and geometric M. Betacetylmethadol 9607 isomers, salts, and salts 19 CSR 30-1.002 Schedules of Controlled N. Beta-hydroxyfentanyl of isomers 9813 Substances (N-(1-(2-hydroxy-2- QQ. 3-Methylthiofentanyl (N- phenethyl)-4-piperidinyl)- (3-methyl-1-(2- PURPOSE: The Department of Health and N-phenylpropanamide) 9830 thienyl)ethyl-4-piperidinyl)- Nphenylpropanamide) 9833 Senior Services has prepared a list of all drugs O. Beta-hydroxy-3- RR. Morpheridine 9632 falling within the purview of controlled sub- methylfentanyl (other name: SS. MPPP (1-methyl-4-phenyl- stances. N-(1-(2-hydroxy-2-phenethyl)- 4-propionoxypiperidine) 9661 3-methyl-4-piperidinyl)-N- TT. MT–45 (1-cyclohexyl- (1) Schedules of Controlled Substances. phenylpropanamide) 9831 (A) Schedule I shall consist of the drugs 4-(1,2-diphenylethyl) P. N-[1-[2-hydroxy-2-(thiophen- piperazine) (9560) and other substances, by whatever official 2-yl) ethyl]piperidin-4-yl]- UU. Noracymethadol 9633 name, common or usual name, chemical N-phenylpropionamide VV. Norlevorphanol 9634 name, or brand name designated, listed in (Other names: WW. Normethadone 9635 this section. Each drug or substance has been beta-hydroxythiofentanyl) 9836 XX. Norpipanone 9636 assigned the Drug Enforcement Administra- Q. Betameprodine 9608 YY. N-(2-fluorophenyl)-2- tion (DEA) Controlled Substances Code R. Betamethadol 9609 methoxy-N- Number set forth opposite it. S. Betaprodine 9611 (1-phenethylpiperidin-4- 1. Opiates. Unless specifically excepted T. Clonitazene 9612 yl)acetamide, its isomers, or unless listed in another schedule, any of esters, ethers, salts, and the following opiates, including their isomers, U. Cyclopropyl fentanyl (N-(1- phenethylpiperidin-4-yl)-N- salts of isomers, esters, and esters, ethers, salts, and salts of isomers, ethers (Other name: esters, and ethers, whenever the existence of phenylcyclopropanecar- boxamide) 9845 ocfentanil) 9838 such isomers, esters, ethers, and salts is pos- ZZ. ortho-Fluorofentanyl (N-(2- sible within the specific chemical designa- V. Dextromoramide 9613 W. Diampromide 9615 fluorophenyl)-N-(1- tion: phenethylpiperidin-4-yl) X. Diethylthiambutene 9616 A. Acetyl-alpha-methylfentanyl propionamide); other name: Y. Difenoxin 9168 (N-(1-(1-methyl-2-phenethyl)- 2-fluorofentanyl) 9816 4-piperidinyl)-N- Z. Dimenoxadol 9617 AAA. para-Fluorobutyryl phenylacetamide) 9815 AA. Dimepheptanol 9618 fentanyl (N- B. Acetylmethadol 9601 BB. Dimethylthiambutene 9619 (4-fluorophenyl)-N-(1- C. Acetyl fentanyl (N-(1- CC. Dioxaphetyl butyrate 9621 phenethylpiperidin-4- phenethylpiperidin-4-yl)- DD. Dipipanone 9622 yl)butyramide) 9823 N-phenylacetamide) 9821 EE. Ethylmethylthiambutene 9623 BBB. Para-fluorofentanyl(N- D. N-(1-phenethylpiperidin-4- FF. Etonitazene 9624 (4-fluorophenyl)-N- yl)-N-phenylacrylamide, GG. Etoxeridine 9625 (1-(2-phenethyl)-4- its isomers, esters, ethers, HH. N-(4-fluorophenyl)-N- piperidinyl) salts, and salts of isomers, (1-phenethylpiperidin-4- propanamide 9812 esters, and ethers (Other yl)isobutyramide, its CCC. PEPAP (1-(-2-phenethyl)- names: acryl fentanyl, isomers, esters, ethers, 4-phenyl-4- acryloylfentanyl) 9811 salts, and salts of isomers, acetoxypiperidine) 9663 E. AH-7921(3,4-dichloro- esters, and ethers (Other DDD. Phenadoxone 9637 N-[(1-dimethylamino) names: 4-fluoroisobutyryl EEE. Phenampromide 9638 cyclohexylmethyl] fentanyl, para- FFF. Phenomorphan 9647 benzamide) 9551 fluoroisobutyryl fentanyl) 9824 GGG. Phenoperidine 9641 F. Allylprodine 9602 II. N-(1-phenethylpiperidin- HHH. Piritramide 9642 G. Alphacetylmethadol (except III. Proheptazine 9643 4-yl)-N-phenylfuran-2- levoalphacetylmethadol JJJ. Properidine 9644 carboxamide (Other names: also known as levo-alpha- KKK. Propiram 9649 acetylmethadol levothadyl furanyl fentanyl) 9834 LLL. Racemoramide 9645 acetate or LAAM) 9603 JJ. Furethidine 9626 MMM. N-(1-phenethylpiperidin- H. Alphameprodine 9604 KK. Hydroxypethidine 9627 4-yl)-N- I. Alphamethadol 9605 LL. Ketobemidone 9628 phenyltetrahydrofuran-2- J. Alpha-methylfentanyl MM. Levomoramide 9629 carboxamide, its (N-1-(alphamethyl-beta- NN. Levophenacylmorphan 9631
Recommended publications
  • Minnesota Statutes 1979 Supplement

    Minnesota Statutes 1979 Supplement

    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
  • Belviq® (Lorcaserin) Patient Information

    Belviq® (Lorcaserin) Patient Information

    Belviq® (lorcaserin) Patient Information Who Is Belviq For? Belviq is a medication for chronic weight management. It is for people with overweight and weight-related conditions or obesity. It is meant to be used together with a lifestyle therapy regimen involving a reduced calorie diet and increased physical activity. How Does Belviq Work? Belviq works in the brain as an appetite suppressant. Who Should Not Take Belviq? Women who are pregnant, nursing, or planning to become pregnant. How Is Belviq Dosed? Belviq® (lorcaserin) Belviq XR® (lorcaserin extended release) Take one 10 mg tablet 2 times each day with Take one 20 mg tablet once daily with or or without food. without food. Is Belviq a Controlled Substance? Belviq is a federally controlled substance because it contains lorcaserin hydrochloride and may be abused or lead to drug dependence. Some states do not allow your doctor to prescribe more than one month at a time. Which Medications Might Not Be Safe to Use with Belviq? Belviq can affect how other medicines work in your body, and other medicines can affect how Belviq works. Tell your doctor about all the medicines and supplements you take, especially those used to treat depression, migraines, or other medical conditions, such as: • Triptans—used to treat migraine headache • Medicines used to treat mood, anxiety, psychotic or thought disorders, including tricyclics, lithium, selective serotonin uptake inhibitors (SSRIs), selective serotonin- norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or antipsychotics • Cabergoline—used to treat a hormone imbalance involving prolactin • Linezolid—an antibiotic • Tramadol—an opioid pain reliever • Dextromethorphan—an over-the-counter medicine used to treat the common cold or cough • Over-the-counter supplements such as tryptophan or St.
  • A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L

    A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L

    Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A.
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun

    (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun

    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
  • SENATE BILL No. 52

    SENATE BILL No. 52

    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
  • Proposed Regulation of the State Board of Pharmacy

    Proposed Regulation of the State Board of Pharmacy

    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R133-14 Workshop July 24, 2014 NAC 453.540 Schedule IV. (NRS 453.146, 639.070) 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: Alprazolam; Barbital; Bromazepam; Butorphanol; Camazepam; Carisoprodol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate; Clotiazepam; Cloxazolam; Delorazepam; Diazepam; Dichloralphenazone; Estazolam; Ethchlorvynol; Ethyl loflazepate; Fludiazepam; Flunitrazepam; --1-- Agency Draft of Proposed Regulation R133-14 Flurazepam; Halazepam; Haloxazolam; Ketazolam; Loprazolam; Lorazepam; Lormetazepam; Mebutamate; Medazepam; Meprobamate; Methohexital; Methylphenobarbital (mephobarbital); Midazolam; Nimetazepam; Nitrazepam; Nordiazepam; Oxazepam; Oxazolam; Paraldehyde; Petrichloral; Phenobarbital; Pinazepam; Prazepam; Quazepam; Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) Temazepam; Tetrazepam; Triazolam; Zaleplon; Zolpidem; or Zopiclone.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • The Melanocortin-4 Receptor As Target for Obesity Treatment: a Systematic Review of Emerging Pharmacological Therapeutic Options

    The Melanocortin-4 Receptor As Target for Obesity Treatment: a Systematic Review of Emerging Pharmacological Therapeutic Options

    International Journal of Obesity (2014) 38, 163–169 & 2014 Macmillan Publishers Limited All rights reserved 0307-0565/14 www.nature.com/ijo REVIEW The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options L Fani1,3, S Bak1,3, P Delhanty2, EFC van Rossum2 and ELT van den Akker1 Obesity is one of the greatest public health challenges of the 21st century. Obesity is currently responsible for B0.7–2.8% of a country’s health costs worldwide. Treatment is often not effective because weight regulation is complex. Appetite and energy control are regulated in the brain. Melanocortin-4 receptor (MC4R) has a central role in this regulation. MC4R defects lead to a severe clinical phenotype with lack of satiety and early-onset severe obesity. Preclinical research has been carried out to understand the mechanism of MC4R regulation and possible effectors. The objective of this study is to systematically review the literature for emerging pharmacological obesity treatment options. A systematic literature search was performed in PubMed and Embase for articles published until June 2012. The search resulted in 664 papers matching the search terms, of which 15 papers remained after elimination, based on the specific inclusion and exclusion criteria. In these 15 papers, different MC4R agonists were studied in vivo in animal and human studies. Almost all studies are in the preclinical phase. There are currently no effective clinical treatments for MC4R-deficient obese patients, although MC4R agonists are being developed and are entering phase I and II trials. International Journal of Obesity (2014) 38, 163–169; doi:10.1038/ijo.2013.80; published online 18 June 2013 Keywords: MC4R; treatment; pharmacological; drug INTRODUCTION appetite by expressing anorexigenic polypeptides such as Controlling the global epidemic of obesity is one of today’s pro-opiomelanocortin and cocaine- and amphetamine-regulated most important public health challenges.
  • Comparative Efficacy and Acceptability of Pharmacological Treatments for Insomnia in Adults: a Systematic Review and Network Meta-Analysis (Protocol)

    Comparative Efficacy and Acceptability of Pharmacological Treatments for Insomnia in Adults: a Systematic Review and Network Meta-Analysis (Protocol)

    Cochrane Database of Systematic Reviews Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis (Protocol) De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L. Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-anal- ysis. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD012364. DOI: 10.1002/14651858.CD012364. www.cochranelibrary.com Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta- analysis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 Figure1. ..................................... 5 ACKNOWLEDGEMENTS . 9 REFERENCES ..................................... 10 APPENDICES ..................................... 14 WHAT’SNEW..................................... 18 CONTRIBUTIONSOFAUTHORS . 18 DECLARATIONSOFINTEREST . 18 Comparative efficacy and acceptability of pharmacological treatments for